South Korea Cancer Diagnostics Market

South Korea Cancer Diagnostics Market Summary

As per Transpire Insight Analysis the South Korea Cancer Diagnostics Market size is estimated at USD 3021.1 Million in 2025 and is anticipated to reach USD 6324.1 Million by 2033, growing at a CAGR of 10.03% from 2026 to 2033.

South Korea’s cancer testing work backs hospitals and labs that want to spot disease earlier. It also lets care teams pick up key tumor details. Then they can choose treatment with more care. The work covers imaging, pathology reviews, lab based molecular tests, and liquid biopsy.

In recent years, the emphasis has changed. Routine screening and tissue based diagnosis are still important. Even so, many groups now put more weight on molecular and genomic tests. There has been more money for precision medicine. Digital pathology has also grown.COVID-19 was a major turning point. During that time, normal screening plans and day to day hospital flow were disrupted. To keep care moving, more diagnostic tasks shifted toward digital routes. It also highlighted that labs must have testing that stays fast and stable.

South Korea also has an older population. Cancer rates are high. Because of that, earlier and more accurate diagnosis matters in routine care. When molecular profiling is done well, doctors can line up patients with options that fit their tumors. Digital tools and automation in lab steps can also reduce wait times and smooth daily work.Overall, these changes are raising the use of advanced diagnostics. You can see it in hospital services. You can also see it in specialty labs built for this work, and in oncology care plans.

South Korea Cancer Diagnostics Market Size & Forecast:

• South Korea Cancer Diagnostics Market Size 2025: USD 3021.1 Million
• Expected Market Value 2033: USD 6324.1 Million
• Forecast CAGR: 10.03%
• Leading region in 2025: 
• Fastest Growing region: 
• Key Profile: Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific, Illumina, Qiagen, bioMérieux, Sysmex Corporation, Becton Dickinson, Fujifilm Healthcare, GE HealthCare, Hologic, Exact Sciences, Samsung Medison 

Key Market Insights

• The Seoul capital area is the top center. In 2025, it will take in about 47% of the healthcare tech market in South Korea. Big hospitals and active research groups support this lead.
• Yeongnam is gaining momentum too. From 2026 to 2034, more funding is moving into diagnostic capacity. Busan and Ulsan are showing steady growth.
• Consumables lead the revenue split. In 2025, they make up 64.32% of sales. Regular testing keeps demand steady, especially for reagents, antibodies, kits, and probes.
• After that, instruments come next. They hold the second place by product share. Hospitals are upgrading tools used in pathology, imaging, and biopsy. The aim is to manage higher-value diagnostic tasks.
• Consumables also rise the fastest from 2026 to 2033. Repeat testing drives this. Molecular diagnostics are being used more often in routine work.
• Breast cancer is still the main use case. At the same time, precision biomarker tests are reshaping diagnosis. This includes breast, lung, colorectal, and stomach cancers.
• Lung cancer testing is growing faster than several other areas. Molecular profiling plays a bigger part here. It supports selection of targeted treatments. It also backs work on companion diagnostics.
• Hospitals and clinics are the key end users. Many have strong oncology services. They also run advanced imaging, pathology, and molecular testing.
• Diagnostic labs are expanding quickly as well. More specialized work is added for molecular tests, biomarkers, and liquid biopsy. These services are now offered beyond hospital-based labs.
• Lunit expanded its AI pathology work through 2025 with partnerships. AstraZeneca, Labcorp, and CellCarta were part of the effort. The result was better biomarker analysis and smoother companion diagnostic workflows.

What are the Key Drivers, Restraints, and Opportunities in the South Korea Cancer Diagnostics Market?

South Korea faces two strains at the same time. The country has more older people. It also has more cancer diagnoses. Because of this, many hospitals are starting tests sooner and trying to make results clearer.In 2024, there were about 292,221 new cancer cases. During the same period, clinicians and labs leaned more on molecular tests and on biomarkers. The goal is to match the right therapy to each case.When tests get more specific, each patient visit can involve several steps. Imaging may come first. Then tissue work. After that, immunohistochemistry. Sequencing can follow. Companion diagnostics may be added as well.

AI is one part of this move. Some tools can reduce the time spent on reading slides. They can also help make biomarker readings steadier and easier to compare. Lunit and AIVIS already offer AI pathology tools. They work with hospitals and drug makers to spread use.Still, there are blockers that slow adoption. Payment rules are a key problem. Another issue is limited proof once tools are used in real care. For SaMD, reimbursement in South Korea can take up to 460 days. On top of that, some products do not receive added payment even if they fall under older billing categories. That makes hospitals hesitate. It also pushes back cash flow for diagnostic AI products.HIRA also looks for stronger evidence. It wants clinical value and cost benefit data. Some AI diagnostic tools end up outside payment coverage. A separate Transpire Insight review of purchase notices and release timing points to supply chain concentration as the main risk once plans start.

Liquid biopsy for early cancer checks across multiple cancer types could be the next move. Samsung made a deal in 2025 with GRAIL. The deal is meant to bring Galleri into South Korea. Samsung plans to make a payment of 110 million dollars as part of the agreement. Around the same time, Korea University and Seer started a 2025 project. They reviewed 20,000 blood plasma samples.In this work, the team will use AI proteomics. They want to find early cancer signals, often called biomarkers.If these plans continue, they could also unlock more funds tied to screening. That may reach further than what routine scans and tissue tests can cover.

What Has the Impact of Artificial Intelligence Been on the South Korea Cancer Diagnostics Market?

Cancer work is moving away from mostly hand reading and toward using computer tools on images. It is also leaning more on numbers for biomarkers and on treatment plans that lean on data. With digital pathology, slides can be scanned fully and then reviewed on screens. Software can highlight possible biomarker signals and make measurements more steady than what a person does alone. This is important because past lab results often depended on how each pathologist interpreted the same slide.

AIVIS is one example. It uses Qanti IHC to measure biomarkers at the cell level. The firm also widened access by teaming up with NAVER Cloud. Lunit has taken a similar route. It has brought AI into pharma projects, clinical studies, and companion diagnostic work. It has worked with groups like AstraZeneca, Labcorp, and CellCarta.

The prediction side is growing as well. AI can look at image patterns and pathology patterns to flag odd findings. It can also estimate how much of a biomarker is present. After that, it can sort patients in a way that supports next step molecular tests. Lunit and AstraZeneca are building AI tools to predict NSCLC mutations from H and E images. If this holds up, it could lower how many people need quick and broad molecular testing.

Labs are also reporting day to day benefits. Reviews can run faster. Quantification can stay more stable. Scaling work across a lab may be simpler. Even so, coverage for payment remains a big barrier. In South Korea, some reviews have asked for stronger clinical proof and better checks on cost value. Some AI tools still do not have coverage in place.

Key Market Trends

• Starting in 2024, AI used in pathology started to pick up speed. Korean groups began teaming up with AstraZeneca, Labcorp, Philips, and other cancer research teams.
• By 2025, Samsung put $110 million into GRAIL. People read that as a signal for faster progress in early checks across multiple cancers. It also pointed to blood based screening methods.
• Molecular diagnostics are getting a louder focus too. Forecasts put this part of the market at USD 835.9 million by 2034. The same reports place it at USD 427.2 million in 2025.
• Roche introduced SBX in 2025. The plan was to make sequencing faster. It was meant to shorten genomic research schedules. It was also set up to back possible oncology uses.
• Seegene acquired DandiMeca in 2025. The deal aimed to push lab automation forward. It centered on running PCR workflows from start to finish with less hands-on work.
• In 2025, AIVIS got support of as much as KRW 1.2 billion through Scale up TIPS. The funding was meant to help move its pan cancer AI biomarker platform ahead.
• Cancer biomarker testing is changing its direction. It is going beyond just diagnosis. It is now tied to risk checks and support for treatment decisions. This turn is linked to work in genomics, proteomics, and ongoing spend on precision medicine.
• In 2025, AIVIS opened more cloud access for pathology using NAVER Cloud. The point was to let more sites use the tool. It also cuts down on each institution having to set up similar systems again.
• Even with all of that, reimbursement stays a key hurdle. Korean AI diagnostic tools will need stronger results from real world use. They will also need clear proof of cost value. That is what will help broader coverage happen.

South Korea Cancer Diagnostics Market Segmentation

By Diagnostic Type : 

Doctors in many hospitals still rely on imaging and tissue biopsy to confirm cancer. Those standard steps let clinicians reach a clear answer fast.Meanwhile, more labs are adding molecular testing. Genetic tests and biomarker panels show up more often now. The goal is to pick therapy that matches the person’s tumor.Doctors are also planning to use liquid biopsy in regular practice. Next-generation sequencing is likely to spread as well. New lab systems run faster. They can profile multiple cancer markers from a small amount of material.

Pathology teams are refining their methods too. Immunohistochemistry can reveal protein markers. Cytology can support screening and diagnosis by examining cells.Hospitals are also looking for tests that can run together. That may boost the usefulness of diagnostic services. It is especially important when care teams need results that connect imaging, tissue results, and molecular findings.

By Cancer Type : 

Cancer care for breast, lung, colorectal, stomach, and prostate cases creates a heavy diagnostic load. Doctors often revisit patients many times for screening, confirmation, staging, and later checks while treatment continues.Lung cancer has gained more attention in recent years. Molecular profiling is used as part of the work. It supports selection of targeted therapy. It can also highlight specific alterations that can be addressed.

Breast cancer still relies on standard steps. Imaging is done at multiple points. Biopsy findings shape the next move. Immunohistochemistry is used often. Biomarker testing shows up in several parts of the care pathway.Blood cancers are handled in a different way. Testing focuses on cells and genes in a more direct manner.Liver cancer and colorectal cancer plans now include more biomarker work. Imaging and tissue review are still used. Markers are just being matched more often with those steps.More programs for early detection are starting up. Screening is increasing as well. Precision oncology approaches are adding additional tests across major cancer types.

By Technology : 

PCR stays popular since it can copy DNA fast. That speed helps when labs and hospitals need testing right away. NGS is also moving ahead. It is more useful as teams use gene data to guide some cancer care and to run studies. Digital slides and AI tools are getting more notice too. They can look at images quickly and in a more repeatable way. That can cut down on how much manual work people do.

Immunoassays still matter in routine work. FISH is used when specific gene changes need a closer look. Mass spectrometry supports its own set of tests. Flow cytometry also keeps a role in specialty workflows. Money for new tools is leaning toward shorter wait times and better measurement. Labs also want more automation. They want systems that connect well across platforms. AI in pathology may spread more as clinical checks build trust. Many hospitals also want ways to handle large batches of images without slowing down.

By End User : 

Hospitals keep using many tools to find and study cancer. One reason is that cancer diagnosis is not a single step. Imaging has to match what tissue shows. Gene testing results need to fit with lab findings. Then the team has to choose a treatment plan that matches all of it.Cancer centers and big university hospitals will likely buy newer systems next. The push is stronger when the case is tough. It is also strong when care teams try precision medicine. Those teams need current testing platforms to keep decisions accurate.Some labs are also doing more narrow molecular tests. This can help hospitals that do not have enough trained staff or the right equipment onsite. In many cases, the lab can run the tests offsite and send the results for care.

Research groups also help build new diagnostic tools. They work on genomics, look for possible biomarkers, and test ideas in real patient studies. The goal is to see if a method holds up outside a lab setting.Some specialty clinics will add only certain diagnostic services too. As more oncology care shifts to outpatient visits, clinics still need the right tests ready on time. When testing needs get more complex, more partnerships start. Hospitals, labs, biotech firms, and tech vendors will team up to meet that load.

By Distribution Channel : 

Hospital procurement is one way to buy advanced imaging tools, pathology devices, sequencing systems, and lab equipment. It still matters a lot, especially when buyers need people to show how the system works in real life.Direct sales can help when the product is complex. Many advanced diagnostic tools need a live demo, correct installation, training for staff, and ongoing support after launch.Diagnostic distributors and lab supply firms also play a role. They often provide reagents, consumables, and the routine items that smaller sites use every day. They can also step in when local buying must move fast and delivery cannot wait.

Government procurement can change the timeline for new equipment. Public health programs and the plans agencies follow are key. Over time, buying should lean more toward reliable inventory, strong technical help, and support that fits as one package. Vendors that group equipment, consumables, software, and maintenance into a single coordinated contract may win more often as diagnostic work becomes more connected.

What are the Key Use Cases Driving the South Korea Cancer Diagnostics Market?

Hospitals are still where most of this work happens. Cancer teams use it for screening, diagnosis, stage finding, and the care plan that follows.In a lot of hospital settings, the purchasing group tracks down imaging gear, biopsy items, lab tests for molecules, and pathology systems. The goal is simple. Oncology services need steady results. New cases can be very frequent, and staff must make calls fast.

Some diagnostic labs are also building their molecular testing teams. They run biomarker checks for hospitals and for cancer centers. In some places, labs ship parts of the work to outside specialists and do not handle every step on site.Medical schools and research centers are adding newer tools too. They use NGS, digital pathology, and AI based systems for studies tied to precision oncology. They also back work that tests and confirms clinical use.

Liquid biopsy may draw more focus in the coming years. Tools tied to AI for early cancer finding may also spread.Public purchasers and big hospital systems may push harder on screening. Work with biotech partners can speed up multi-cancer testing. Those partnerships can also support decisions on treatment that fits the patient.

Which Regions are Driving the South Korea Cancer Diagnostics Market Growth?

Seoul Capital Area stays in first place. It makes up about 47% of healthcare tech work in South Korea. The area has many hospitals close together. It also includes big teaching medical centers. That mix helps new cancer tests move into clinics faster. Samsung, Lunit, and other firms get an edge here too. Large hospital groups, research centers, and drug makers are nearby. Strong clinical volume and heavy research spending should keep the lead in place through 2033. Precision oncology and AI aided diagnostic tools will likely keep growing.

Yeongnam looks more like an industry spread across several cities. Busan and Ulsan help drive the demand. They have major hospitals, medical centers, and research sites. Local support for public healthcare stays steadier than in some other places. Ongoing upgrades to regional health facilities also matter. These factors give a solid base for test devices and lab services. Good transport routes help as well. They make it easier to ship scanners, reagents, and other lab supplies. Buyers at local institutions tend to stay active. That should keep Yeongnam as a steady source of revenue during the whole forecast window.

Bio work in Chungcheong is picking up quickly. Teams are moving toward the areas around Daejeon and Osong. New research sites and upgraded medical centers are part of why this is happening. Funding has also gone into biohealth cluster projects. That money has strengthened local research. As a result, diagnosis companies are linking more often with hospitals, schools, and drug manufacturers.When biotech stays clustered, more tools tend to follow. This can mean molecular diagnostics, NGS, liquid biopsy, and tests that use AI. From 2026 to 2033, suppliers that work through research agreements and hospital ties should be able to move into the regional market more easily.

Who are the Key Players in the South Korea Cancer Diagnostics Market and How Do They Compete?

In South Korea, cancer diagnostics are changing as newer tools move in. Still, big hospital groups, lab chains, and outside vendors keep influence over purchases. Many buyers focus more on results than on price. They want tests that are accurate, quick to report, and easy to run with automation. They also ask for clinical evidence that makes sense, plus smooth connections to hospital IT.

Some firms try to stay on top by listing more tests. Others try to slip into smaller openings. A few lean on AI helpers, molecular testing, or digital pathology.Lunit is known for AI tools that support image and pathology review. The company has ties with AstraZeneca, Labcorp, and CellCarta. Those partnerships back work in biomarker projects and companion diagnostics. AIVIS uses digital pathology in a more measured style. Its Qanti IHC is built to make biomarker numbers more steady across runs. It also pushes wider access by using NAVER Cloud.

Seegene is working toward tighter lab automation. It acquired DandiMeca. The aim is to connect PCR steps better, so labs need fewer manual actions. Roche is also active in this space. It is using newer sequencing methods. Roche plans to roll out SBX in 2025 to speed up genomic analysis.Samsung is heading down a different route. It put $110 million into GRAIL. It also helps with Galleri’s commercialization. That move gives more reach for early detection across multiple cancer types. It supports blood based screening efforts too.

Company List

• Roche Diagnostics
• Abbott Laboratories
• Siemens Healthineers
• Danaher Corporation
• Thermo Fisher Scientific
• Illumina
• Qiagen
• bioMérieux
• Sysmex Corporation
• Becton Dickinson
• Fujifilm Healthcare
• GE HealthCare
• Hologic
• Exact Sciences
• Samsung Medison 

Recent Development News

In March 2026, Lunit entered a strategic collaboration with CellCarta to accelerate AI-enabled companion diagnostic development and commercialization. The agreement integrates Lunit SCOPE into CellCarta clinical workflows for biomarker strategy, quantitative IHC, immunophenotyping, clinical-trial testing, and CDx preparation, strengthening AI pathology adoption in oncology. Source https://www.lunit.io/

In February 2025, Seegene acquired DandiMeca to develop fully automated PCR diagnostic equipment. The acquisition adds robotics and automation capabilities to Seegene’s portfolio, supporting development of systems that automate the full PCR testing process and expand laboratory efficiency. Source https://kr.seegene.com/

What Strategic Insights Define the Future of the South Korea Cancer Diagnostics Market?

Over the next five to seven years, cancer testing in South Korea may shift to a mix of methods rather than one single approach. Teams are likely to use NGS, molecular markers, digital pathology, and liquid biopsy more often, along with CT and MRI style scans and tissue samples.

One key reason is the tie between diagnosis and the treatment plan. When tests are more accurate, clinicians can choose the right therapy sooner. That push can also lead to new testing paths that feel more useful in real practice.There is a downside that can be missed at first. If testing becomes centered in a small number of big hospitals, with heavy involvement from large equipment vendors and only a few specialty labs, some patients may not get the same access. Tool purchases can also stall if one platform is difficult to switch out later. On top of that, slow payor coverage decisions can add stress for both systems and patients.

A newer area to watch is AI paired with liquid biopsy. Blood tests that search for circulating tumor DNA may aid earlier detection. They may also help follow how well treatment is doing, even when tissue testing is not available.More papers are also pointing to machine learning applied to liquid biopsy data. Firms should aim for tools that fit with other testing steps. They also need clinical partnerships that connect molecular testing, pathology workflows, and AI use. At the same time, they must show local results that support reimbursement choices.

South Korea Cancer Diagnostics Market Report Segmentation

By Diagnostic Type

• Imaging
• Biopsy
• Molecular Diagnostics
• Genetic Testing
• Liquid Biopsy
• Biomarker Testing
• Immunohistochemistry
• Cytology
• Next-Generation Sequencing

By Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Stomach Cancer
• Cervical Cancer
• Blood Cancer

By Technology

• PCR
• NGS
• Immunoassay
• FISH
• Mass Spectrometry
• Digital Pathology
• AI-Based Diagnostics
• Flow Cytometry

By End User

• Hospitals
• Diagnostic Laboratories
• Cancer Centers
• Research Institutes
• Academic Medical Centers
• Specialty Clinics

By Distribution Channel

• Hospital Procurement
• Diagnostic Distributors
• Direct Sales
• Laboratory Suppliers
• Government Procurement